The role of azacitidine in the management of myelodysplastic syndromes (MDS)

por Götze, KS, Müller-Thomas, C, Peschel, C
Publicado 2009

cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro.

por Bug, G, Aman, J, Huber, C, Peschel, C, Derigs, H G
Publicado 1998

Correction to: Prospective multicentre randomized double‑blind placebo‑controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent sympt...

por Nestler, S., Peschel, C., Horstmann, A. H., Vahlensieck, W., Fabry, W., Neisius, A.
Publicado 2023

Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent symptomatic uncompli...

por Nestler, S., Peschel, C., Horstmann, A. H., Vahlensieck, W., Fabry, W., Neisius, A.
Publicado 2022

Induction of the pro-myelocytic leukaemia gene by type I and type II interferons.

por Heuser, M, van der Kuip, H, Falini, B, Peschel, C, Huber, C, Fischer, T
Publicado 1998

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer

por Lordick, F, von Schilling, C, Bernhard, H, Hennig, M, Bredenkamp, R, Peschel, C
Publicado 2003

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

por Lorenzen, S, Duyster, J, Lersch, C, von Delius, S, Hennig, M, Bredenkamp, R, Peschel, C, Lordick, F
Publicado 2005

P70. Development of clinically implementable imaging strategies for tracking T cell receptor-transgenic T cells

por Mall, S, D'Alessandria, C, Aichler, M, Walch, A, Essler, M, Schwaiger, M, Peschel, C, Krackhardt, A
Publicado 2014

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation

por Sigl, M, Spoerl, S, Schnittger, S, Meissner, J, Rummelt, C, Peschel, C, Duyster, J, Ho, A D, von Bubnoff, N
Publicado 2013

P69. Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias

por Richard, K, Schober, S, Rami, M, Mall, S, Merl, J, Slotta-Huspenina, J, Stevanovic, S, Busch, DH, Peschel, C, Krackhardt, AM
Publicado 2014

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes

por Brackertz, B, Conrad, H, Daniel, J, Kast, B, Krönig, H, Busch, D H, Adamski, J, Peschel, C, Bernhard, H
Publicado 2011

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

por Lordick, F, Luber, B, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Wöll, E, Decker, T, Endlicher, E, Röthling, N, Schuster, T, Keller, G, Fend, F, Peschel, C
Publicado 2010

Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: resu...

por Lorenzen, S, Brücher, B, Zimmermann, F, Geinitz, H, Riera, J, Schuster, T, Roethling, N, Höfler, H, Ott, K, Peschel, C, Siewert, J R, Molls, M, Lordick, F
Publicado 2008

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer

por Lordick, F, Lorenzen, S, Stollfuss, J, Vehling-Kaiser, U, Kullmann, F, Hentrich, M, Zumschlinge, R, Dietzfelbinger, H, Thoedtmann, J, Hennig, M, Seroneit, T, Bredenkamp, R, Duyster, J, Peschel, C
Publicado 2005